Isatuximab

New therapeutic options for tailored and selective treatment of multiple myeloma 3:48
New therapeutic options for tailored and selective treatment of multiple myeloma
Paul Richardson
CD38: a promising target for multiple myeloma antibody therapy 4:52
CD38: a promising target for multiple myeloma antibody therapy
Saad Usmani
The role of immunotherapy in non-transplant eligible multiple myeloma 6:56
The role of immunotherapy in non-transplant eligible multiple myeloma
Xavier Leleu
Daratumumab in the management of AL amyloidosis 5:07
Daratumumab in the management of AL amyloidosis
Morie Gertz
Management of relapsed/refractory myeloma 4:44
Management of relapsed/refractory myeloma
Maria-Victoria Mateos
Rise of antibody-based treatments in myeloma 1:25
Rise of antibody-based treatments in myeloma
Sagar Lonial
Chemotherapy-free approaches to AL amyloidosis 2:55
Chemotherapy-free approaches to AL amyloidosis
Suzanne Lentzsch
Current CAR-T climate in multiple myeloma 8:11
Current CAR-T climate in multiple myeloma
Noopur Raje
Therapeutic options for hard to treat R/R myeloma 5:52
Therapeutic options for hard to treat R/R myeloma
Mohamad Mohty
Induction and front-line therapy for myeloma 3:59
Induction and front-line therapy for myeloma
Maria-Victoria Mateos
GMMG-CONCEPT: Isa-KRd in front-line treatment of high-risk myeloma 5:17
GMMG-CONCEPT: Isa-KRd in front-line treatment of high-risk myeloma
Katja Weisel
ICARIA-MM: isatuximab, pomalidomide & dexamethasone 3:54
ICARIA-MM: isatuximab, pomalidomide & dexamethasone
Meral Beksac
Immunomodulation for improving long-term outcomes in myeloma 5:18
Immunomodulation for improving long-term outcomes in myeloma
Michel Delforge
IKEMA: kD vs isatuximab and kD in R/R myeloma 4:30
IKEMA: kD vs isatuximab and kD in R/R myeloma
Philippe Moreau
The role of isatuximab in the management of MM 3:54
The role of isatuximab in the management of MM
Mohamad Mohty
Management of R/R myeloma and MRD assessment 4:40
Management of R/R myeloma and MRD assessment
Elena Zamagni
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals